Login
Home
Charts
Search
Watchlist
Products

GPT Healthcare Ltd

GPTHEALTH·NSE
161.79-0.61%Wed, 23 Sept '26 12:58

GPT Healthcare Ltd

GPTHEALTH
NSE
161.79
-0.61%
|Wed, 23 Sept '26 12:58
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
1,326Cr
Close
Close Price
161.65
Industry
Industry
Hospitals
PE
Price To Earnings
28.06
PS
Price To Sales
2.70
Revenue
Revenue
492Cr
Rev Gr TTM
Revenue Growth TTM
18.07%
PAT Gr TTM
PAT Growth TTM
-0.78%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
108979998106102101107119120126126
Growth YoY
Revenue Growth YoY%
3.93.51.7-2.15.82.09.512.517.624.617.8
Expenses
ExpensesCr
83767680828181909699103102
Operating Profit
Operating ProfitCr
252123182321211723212324
OPM
OPM%
22.821.723.318.422.220.820.416.219.117.218.519.2
Other Income
Other IncomeCr
112232221122
Interest Expense
Interest ExpenseCr
222111122222
Depreciation
DepreciationCr
455555567777
PBT
PBTCr
191618152118161115131617
Tax
TaxCr
656565334314
PAT
PATCr
1411131015121381191513
Growth YoY
PAT Growth YoY%
37.423.8-0.29.86.80.6-22.9-28.5-23.513.065.8
NPM
NPM%
12.511.912.910.214.012.012.77.28.97.811.510.1
EPS
EPS
1.71.41.61.21.81.51.60.91.31.11.81.6
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
108979998106102101107119120126126
Growth YoY
Revenue Growth YoY%
3.93.51.7-2.15.82.09.512.517.624.617.8
Expenses
ExpensesCr
83767680828181909699103102
Operating Profit
Operating ProfitCr
252123182321211723212324
OPM
OPM%
22.821.723.318.422.220.820.416.219.117.218.519.2
Other Income
Other IncomeCr
112232221122
Interest Expense
Interest ExpenseCr
222111122222
Depreciation
DepreciationCr
455555567777
PBT
PBTCr
191618152118161115131617
Tax
TaxCr
656565334314
PAT
PATCr
1411131015121381191513
Growth YoY
PAT Growth YoY%
37.423.8-0.29.86.80.6-22.9-28.5-23.513.065.8
NPM
NPM%
12.511.912.910.214.012.012.77.28.97.811.510.1
EPS
EPS
1.71.41.61.21.81.51.60.91.31.11.81.6

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
212243337361400407473492
Growth
Revenue Growth%
14.639.07.010.81.716.118.1
Expenses
ExpensesCr
176194264287312324388401
Operating Profit
Operating ProfitCr
3649747488838491
OPM
OPM%
16.920.221.920.621.920.517.818.5
Other Income
Other IncomeCr
46565866
Interest Expense
Interest ExpenseCr
14141197389
Depreciation
DepreciationCr
1112141518192728
PBT
PBTCr
1529545668695561
Tax
TaxCr
48121720191314
PAT
PATCr
1121423948504247
Growth
PAT Growth%
92.597.5-6.422.54.5-15.4-0.8
NPM
NPM%
5.28.712.310.811.912.38.99.6
EPS
EPS
4.17.95.24.96.06.15.25.8
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
212243337361400407473492
Growth
Revenue Growth%
14.639.07.010.81.716.118.1
Expenses
ExpensesCr
176194264287312324388401
Operating Profit
Operating ProfitCr
3649747488838491
OPM
OPM%
16.920.221.920.621.920.517.818.5
Other Income
Other IncomeCr
46565866
Interest Expense
Interest ExpenseCr
14141197389
Depreciation
DepreciationCr
1112141518192728
PBT
PBTCr
1529545668695561
Tax
TaxCr
48121720191314
PAT
PATCr
1121423948504247
Growth
PAT Growth%
92.597.5-6.422.54.5-15.4-0.8
NPM
NPM%
5.28.712.310.811.912.38.99.6
EPS
EPS
4.17.95.24.96.06.15.25.8

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
18188080828282
Reserves
ReservesCr
69767885136166187
Current Liabilities
Current LiabilitiesCr
65606882777479
Non Current Liabilities
Non Current LiabilitiesCr
11712397805062116
Total Liabilities
Total LiabilitiesCr
308317323327346384465
Current Assets
Current AssetsCr
63868681807989
Non Current Assets
Non Current AssetsCr
246231238245265305375
Total Assets
Total AssetsCr
308317323327346384465
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
18188080828282
Reserves
ReservesCr
69767885136166187
Current Liabilities
Current LiabilitiesCr
65606882777479
Non Current Liabilities
Non Current LiabilitiesCr
11712397805062116
Total Liabilities
Total LiabilitiesCr
308317323327346384465
Current Assets
Current AssetsCr
63868681807989
Non Current Assets
Non Current AssetsCr
246231238245265305375
Total Assets
Total AssetsCr
308317323327346384465

Cash Flow

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
41436666696781
Investing Cash Flow
Investing Cash FlowCr
-54-16-55-25-33-47
Financing Cash Flow
Financing Cash FlowCr
12-22-57-73-49-35-31
Net Cash Flow
Net Cash FlowCr
-143-2-502
Free Cash Flow
Free Cash FlowCr
-5385958501840
CFO To PAT
CFO To PAT%
378.4203.8158.4170.1144.0135.0192.2
CFO To EBITDA
CFO To EBITDA%
115.887.889.489.378.380.996.4
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
41436666696781
Investing Cash Flow
Investing Cash FlowCr
-54-16-55-25-33-47
Financing Cash Flow
Financing Cash FlowCr
12-22-57-73-49-35-31
Net Cash Flow
Net Cash FlowCr
-143-2-502
Free Cash Flow
Free Cash FlowCr
-5385958501840
CFO To PAT
CFO To PAT%
378.4203.8158.4170.1144.0135.0192.2
CFO To EBITDA
CFO To EBITDA%
115.887.889.489.378.380.996.4

Ratios

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1,4481,2049441,326
Price To Earnings
Price To Earnings
30.324.122.328.1
Price To Sales
Price To Sales
3.63.02.02.7
Price To Book
Price To Book
6.64.93.54.9
EV To EBITDA
EV To EBITDA
16.714.812.215.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
47.448.445.546.347.348.647.447.4
OPM
OPM%
16.920.221.920.621.920.517.818.5
NPM
NPM%
5.28.712.310.811.912.38.99.6
ROCE
ROCE%
15.021.225.126.330.225.717.517.5
ROE
ROE%
12.622.526.323.621.920.115.715.7
ROA
ROA%
3.56.712.911.913.813.09.19.1
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
1,4481,2049441,326
Price To Earnings
Price To Earnings
30.324.122.328.1
Price To Sales
Price To Sales
3.63.02.02.7
Price To Book
Price To Book
6.64.93.54.9
EV To EBITDA
EV To EBITDA
16.714.812.215.9
Profitability Ratios
Profitability Ratios
GPM
GPM%
47.448.445.546.347.348.647.447.4
OPM
OPM%
16.920.221.920.621.920.517.818.5
NPM
NPM%
5.28.712.310.811.912.38.99.6
ROCE
ROCE%
15.021.225.126.330.225.717.517.5
ROE
ROE%
12.622.526.323.621.920.115.715.7
ROA
ROA%
3.56.712.911.913.813.09.19.1
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
GPT Healthcare runs a chain of mid-sized, neighbourhood hospitals that bring advanced tertiary care - including robotic surgery and oncology - directly into the residential heart of underserved cities in Eastern and Central India. Founded in 2000 with an 8-bed facility in Kolkata, the company has grown under the clinical stewardship of a surgeon with over 40 years of experience into a listed, net-debt-free network of five hospitals. Its recurring approach is a disciplined, asset-light model: it builds right-sized hospitals on long-term leases in markets with low bed density, then drives returns by steadily improving the mix of complex surgeries and the utilisation of its existing beds. # Business segments A single engine - a network of five owned hospitals, each a full-service tertiary centre in a specific city, generating revenue from the same fee-for-service model and sharing a common clinical and operational backbone. ## 1. ILS Hospitals network: a chain of neighbourhood tertiary-care centres **The company earns a fee for every consultation, procedure and room night across five mid-sized hospitals, with nearly all payments coming from cash and insurance patients rather than government schemes.** - **Paid per service, not per patient** - revenue comes from inpatient and outpatient charges on a fee-for-service basis, covering accommodation, theatre use, professional fees, equipment, radiology, laboratory tests and pharmacy goods. - **Cash and insurance payers keep cash flows healthy** - roughly 90-95% of patient business comes from cash and insurance-paying individuals, with very low exposure to government schemes or corporate contracts, so the company avoids the delayed payments and margin pressure that come with public reimbursement. - **Complexity lifts the average bill** - the network’s average revenue per occupied bed rose from about INR 32,947 in FY24 to INR 39,243 in FY26, driven by a stronger clinical mix of robotic surgeries, transplants and oncology rather than by simply raising prices. - **Ten specialties spread the risk** - approximately 87% of revenue is contributed by ten specialties, with internal medicine, nephrology and general surgery as the largest, so no single department dominates the top line. - **Occupancy is managed, not maximised** - the company consciously keeps occupancy around 75-80% at mature hospitals to avoid stretching beds and clinical resources, with network occupancy at roughly 56% excluding the newly opened Raipur hospital. ### 1.1 ILS Salt Lake: the flagship for robotic surgery **An 85-bed surgical hospital that anchors the network’s reputation for complex, technology-driven procedures.** - **Robotics as the differentiator** - the hospital performed over 800 robotic surgeries in FY26, primarily in gastro and bariatric procedures, which reduced the average length of stay from 4 to 3.2 days and pushed ARPOB to INR 43,800 in the fourth quarter. - **A teaching centre for surgeons** - it houses an NBE-accredited Minimal Access Surgery department that trains post-graduate surgeons under a national fellowship programme, reinforcing its standing as a referral centre. - **The only comprehensive cancer centre in the state** - with a linear accelerator, PET scan and radiation oncology unit commissioned in mid-2025, it offers end-to-end oncology care that no other hospital in Tripura provides. - **Medical value travel from across the border** - the hospital attracts international patients, particularly from Bangladesh, a segment that historically contributed up to 10% of its revenue and is now recovering after political disruptions. - **First-of-its-kind procedures in the region** - it has performed Tripura’s first complex vascular stenting and dual-chamber leadless implantation, as well as infant cochlear implant and congenital heart surgeries. ### 1.3 ILS Dum Dum: the turnaround in critical care **A 155-bed facility that was restructured into a high-occupancy centre for renal transplants and cardiac care.** - **Renal transplants drive volumes** - the Dumdum hospital performed 190 renal transplants in FY24, which historically kept its average length of stay higher at around 5.2 days. - **Turnaround through tighter operations** - occupancy reached 71% in the fourth quarter of FY26 after restructuring initiatives, while length of stay was brought down from 4.59 to 4.47 days. - **Robot-assisted knees in a catchment with no rival** - the hospital launched robotic knee replacements and performed nearly 100 robotic surgeries in just over a year, drawing patients from a large, uncontested catchment area fed by the railway station. - **Broke even in eight months** - it achieved EBITDA breakeven within eight months of inauguration, which the company describes as one of the fastest timelines in India’s tertiary care hospital sector. - **Built for INR 47 lakh per bed on a fixed lease** - the INR 74 crore investment was made on a 27-year lease with the developer, so the company carries no land or building ownership on its books. - **High-end equipment from day one** - it opened with a 3 Tesla MRI, cardiac catheterisation lab and dual-source CT scanner, and has already completed six renal transplants and received a liver transplant licence. - **Breakeven expected at just 30% occupancy** - the company projects EBITDA breakeven within approximately 15 months, requiring an occupancy level of only around 30%, because the fixed-lease model keeps operating leverage high. # Technology and digital backbone **A shared digital and clinical-technology layer connects all five hospitals, making patient access self-service and enabling complex procedures across the network.** - **Self-service access for patients** - the “ILS-MyHealth” mobile app lets patients book appointments, view medical records and access hospital information without human intervention, while a central HMIS pushes reports directly via WhatsApp and email. - **Home care for the elderly** - the “SPARSH” programme offers senior citizens monthly doctor visits, routine checks, discounts on diagnostics and priority admission for an annual fee of INR 500, creating a feeder channel into the hospitals. - **Robotics and advanced imaging as a network standard** - robotic surgical systems are installed at Salt Lake and Howrah Hospital, 3D imaging supports interventional neurology at Dum Dum, and PET scans with linear accelerators run oncology at Agartala, so complex care is not confined to one flagship. # Group structure and partners **The company is a single legal entity with no subsidiaries, directly owning and operating all five hospitals under a promoter-led board.** - **Wholly owned, single-segment structure** - GPT Healthcare Limited operates all hospitals directly with no joint ventures or associate companies, so all cash flows and decision-making sit within one entity. - **Asset-light partners, not co-investors** - the Raipur and upcoming Jamshedpur hospitals are built under long-term leases with unrelated developers who fund the land and construction, while the cancer care department at Agartala is operated under a management agreement with International Oncology Services.

Documents — GPT Healthcare Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/edajdan1bwj460e87kg7vn9y.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/rzz0oqv18t1s993sk9kewp8f.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/us1s21ejw78ac2sl23cokrfe.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/n9nzpgd0hkkcyy5s0vy7mzbb.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/vjg012fhcnfskdrij068txh7.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/l2sutoyogk14w6bynjrxlsyo.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/ma3wcdj52sqsky2lt0eak6mq.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/jgb1qmme8yivhvi2zwny1jfr.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/qqc3rvivi4paa393femo8kk0.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/a7k3i9cb0k9x18m288q6slai.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/l3g3ih5c24jo4k04oshlw5cd.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/s0l69gizr8c6m734foea249w.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/ct9ejd2qz33eslwoe5hepd61.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/xy4djkazk3aipvcwm5c7w02p.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/3wegoq6s70o0ct7oy6sikpln.pdf
  • Q1 FY2025 Quarterly Result (Jun 2024, PDF): https://www.stockscans.in/document/cr7j7bq8naxuunnglkrpd3lb.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/ufwa1yyxram0vzmdccd66f6w.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/dxv45035b17wx57soq2v1fw4.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/l3550c4gqlkfye1f6r0rjnik.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/z1omzxutn0i5be74hrhblybb.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/qxusci2ym366c7tm7mthomky.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/ff4hmhyoj1b9vjalv94uqq7t.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/1huislnq0cx47r5exww9x5eo.pdf
  • Q1 FY2025 Investor Presentation (Jun 2024, PDF): https://www.stockscans.in/document/4t20nlz15m3ywnyrl02qg8iq.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/26qdhymih5kopl7m245fpuag.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/5rv2o7h5e3n000uzpzpdmz3j.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/j7vdrlk1g7p361ro1ewmen1x.pdf

Concall Transcript Summaries — GPT Healthcare Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202606/edajdan1bwj460e87kg7vn9y.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202603/rzz0oqv18t1s993sk9kewp8f.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202512/us1s21ejw78ac2sl23cokrfe.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202509/n9nzpgd0hkkcyy5s0vy7mzbb.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202506/vjg012fhcnfskdrij068txh7.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202503/l2sutoyogk14w6bynjrxlsyo.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202412/ma3wcdj52sqsky2lt0eak6mq.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AGPTHEALTH/transcript-notes/202409/jgb1qmme8yivhvi2zwny1jfr.pdf